The effect of piracetam (a putative enhancer of cerebral metabolism) on regional CMRalu was studied by positron emission tomography of 2[18Fl-fluoro-2-deoxY-D-glucose in nine patients with Alzheimer's dis ease, and in seven cases with multiinfarct dementia or unclassified dementia. In Alzheimer's disease, i. v. ad ministration of piracetam, 6 g b.i.d. for 2 weeks, signifi cantly improved rCMRalu in most cortical areas, whereas no effect on CMRalu of the drug was observed in the mul tiinfarct dementia/unclassified dementia groups. These Several therapeutic strategies have been shown to be effective in improving some of the clinical signs and symptoms of senile or presenile degener ative dementia of the Alzheimer type (Alzheimer's disease). These attempts included efforts to correct for a suspected specific deficit of choline acetyl transferase (Davies and Maloney, 1976) and a loss of cholinergic neurons (Coyle et aI., 1983) by sub stitution with cholinergic drugs, especially cholin esterase inhibitors, e.g., physostigmine (Davis et aI., 1978), and recently the potent, centrally acting tetrahydroaminoacridine (Summers et aI., 1986). Although acetylcholine precursors were not clini cally effective when given alone (review in Kurz et aI., 1986; Hollander et aI., 1986), combinations with drugs like piracetam enhancing cerebral metabo-
results lend further support to the notion that adjuvant piracetam treatment is of benefit in Alzheimer's disease. They may also indicate that the typical metabolic depres sion in Alzheimer's disease is caused by complex interac tion of disturbed transmitter and cellular function rather than by a specific deficit in the cholinergic system alone. Key Words: Cerebral glucose metabolism-Alzheimer's disease-Multiinfarct dementia-Piracetam -Positron emission tomography. lism substantially ameliorated selective memory deficits in Alzheimer's disease patients (Ferris et aI., 1982; Smith et aI., 1984) . Studies of glucose me tabolism by positron emission tomography (PET) have demonstrated a reduction of regional CMRGlu most prominent in the precentral and parietotem poral lobes (Benson et aI., 1983; Foster et aI., 1983; De Leon et aI., 1983; Cutler et aI., 1985; Friedland et aI., 1985; Szelies et aI., 1986) . However, effects of drugs on disturbed glucose metabolism in Alz heimer's disease have not been described so far. In the following, we provide the first demonstration of a drug's ability to improve the disturbed glucose metabolism characteristic of Alzheimer's disease.
MATERIALS AND METHODS
Sixteen consecutive patients (seven men, nine women; mean age, 60.7 years; range, 44-76 years) admitted to the hospital because of progressive intellectual deterioration were studied. Careful general medical and neurological examination ruled out medical illness, history of trauma, or drug abuse as the cause of dementia. All patients met DSM-III (American Psychiatric Association, 1980) clin- ical criteria of dementia and were examined using the mini-mental test (Folstein et al., 1975) , the dementia scale (Blessed et al., 1968) , and an ischemic score (Hachinski et al., 1975) . Nine patients were classified as probable Alzheimer's disease (McKhann et al., 1984) , with three being mildly, four moderately, and two severely de mented. Their duration of illness ranged between 6 months and 5 years (median, 3 years). The other seven cases not meeting these criteria were classified as non Alzheimer's dementia. Four of them had an ischemic score >8, characterizing them as multiinfarct dements.
Three patients had a mixed vascular/degenerative type of dementia. The median duration of illness in the non-Alz heimer group was 2 years (range, 6 months-3 years), their mean age was comparable to the Alzheimer pa tients. 1\\' 0 had a mild and five had a moderate dementia. In all cases, gross pathological changes other than mild to moderate brain atrophy were ruled out by X-ray com puted tomography. In particular, there were no major in farcts, tumors, or focal atrophy. Informed consent as to inclusion in the therapeutic study and to the PET examinations was obtained from subjects and their families. None refused to participate.
All patients received 6 g piracetam in 250 ml 5% levulose intravenously within 1 h, twice daily for 14 days. Before and immediately after the treatment period, rCMRGlu was studied with 2[ 1 8F]-2-deoxY-D-glucose (FDG) and PET (Reivich et al., 1979) , using a four-ring positron camera (Scanditronix PC 384). All studies were performed with patients in a resting state with eyes closed and ears un plugged, in a darkened room with low ambient noise. One hundred eighty-five Bq (5 mCi) FDG [synthesized ac cording to the procedure of Hamacher et al. (1986) without 2-deoxy-2-fluoromannose] were ir\iected intrave nously. Investigative and scanning procedures, and image processing are elsewhere described in detail (Heiss et al., 1984) . CMR GIu was calculated with rate constants ad justed for the measured tissue activities according to the k 1 •3-optimization procedure re quiring less stringent assumptions about the tracer be havior in abnormal tissue. Standardized regional quanti tation was achieved using an interactive mapping pro gram (Herholz et aI., 1985) . A categorical region matching and block shifting procedure (Pawlik et aI., 1986) provided optimal comparability both among sub-
Difference 1st meas. Difference 8.0 ± 7.710 37.9 ± 6.91 -1.3 ± 10.46 8.5 ± 7.760
38.3 ± 7.22 -2.2 ± 9.23 3.7 ± 8.59
34.9 ± 5.74 1.1 ± 7.28 9.9 ± 8.720
37.0 ± 6.10 -1.8 ± 10.62 10.3 ± 12.030 40.4 ± 7.59 -4.8 ± 12.33 9.1 ± 8.840
38.51 ± 7.33 1.1 ± 14.77 3.2 ± 10.92
27.51 ± 4.64 1.8 ± 9.4 8.4 ± 6.920 40.6 ± 7.86 -0.6 ± 11.37 7.7 ± 10.320 37.9 ± 6.82 -0.3 ± 8.63 0.6 ± 7.00 26.3 ± 4.75 -4.7 ± 11.78 0.2 ± 9.15 31.6 ± 5.89 1.6 ± 12.86 2.2 ± 6.54 17.7 ± 4.02 -5.1 ± 8.76
jects and between data of the same patient. Statistical assessment of treatment effects and of potential hemi spheric or regional differences was performed by re peated-measures analysis of variance using Huynh Feldt-adjusted degrees of freedom (SAS* procedure GLM, with regions, hemispheres, pre-and posttreat ment values representing within-factors), and by two tailed paired t tests in both dementia groups. (Summers et aI., 1986) .
RESULTS

In
The purpose of our study was not to prove the clin-ical efficacy, but to support a therapeutic rationale based on enhancing cellular metabolism, which then might optimize the incorporation of acetylcho line precursors or the effectiveness of the trans mitter available at higher concentrations after cho linesterase inhibition. Our results, therefore, may help in the interpretation of beneficial clinical re sults with combinations of piracetam and acetyl choline precursors, which could not be obtained with either drug alone (Ferris et al., 1982; Smith et al., 1984) .
The effect of piracetam was mainly seen in cere bral cortex of Alzheimer's disease patients but not in subcortical structures. This corresponds with the gross anatomical distribution of pathological (McGeer et al., 1986) and metabolic alterations (Ferris et al., 1980; Benson et al., 1983; De Leon et al., 1983; Friedland et al., 1985; Cutler et al., 1985) .
Metabolic dysfunction in multiinfarct dementia shows less distinct anatomical prediction, and met abolic alterations are usually scattered all over the brain (Benson et al., 1983) . 
